Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Provectus Biopharmaceuticals Inc (PVCT)

Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,175
  • Shares Outstanding, K 420,280
  • Annual Sales, $ 620 K
  • Annual Income, $ -4,760 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.68
  • Price/Sales 45.77
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $0.00 on 11/13/25
  • Next Earnings Date 03/26/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0500 +19.80%
on 11/25/25
0.0750 -20.13%
on 11/21/25
-0.0099 (-14.18%)
since 11/19/25
3-Month
0.0500 +19.80%
on 11/25/25
0.0900 -33.44%
on 10/01/25
-0.0051 (-7.85%)
since 09/19/25
52-Week
0.0500 +19.80%
on 11/25/25
0.1287 -53.46%
on 12/20/24
-0.0695 (-53.71%)
since 12/19/24

Most Recent Stories

More News
Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy

KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical...

PVCT : 0.0599 (-10.86%)
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer

KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its...

PVCT : 0.0599 (-10.86%)
Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

PVCT : 0.0599 (-10.86%)
Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

PVCT : 0.0599 (-10.86%)
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs

PVCT : 0.0599 (-10.86%)
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics

KNOXVILLE, TN / ACCESSWIRE / January 14, 2025 / VisiRose Inc. ("VisiRose" or the "Company"), a privately-held, clinical-stage biotechnology company developing novel ocular therapeutics, today announced...

PVCT : 0.0599 (-10.86%)
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics

KNOXVILLE, TN / ACCESSWIRE / January 14, 2025 / VisiRose Inc. ("VisiRose" or the "Company"), a privately-held, clinical-stage biotechnology company developing novel ocular therapeutics, today announced...

PVCT : 0.0599 (-10.86%)
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology

PVCT : 0.0599 (-10.86%)
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals

PVCT : 0.0599 (-10.86%)
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals

PVCT : 0.0599 (-10.86%)

Business Summary

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus...

See More

Key Turning Points

3rd Resistance Point 0.0661
2nd Resistance Point 0.0630
1st Resistance Point 0.0615
Last Price 0.0599
1st Support Level 0.0569
2nd Support Level 0.0538
3rd Support Level 0.0523

See More

52-Week High 0.1287
Fibonacci 61.8% 0.0986
Fibonacci 50% 0.0894
Fibonacci 38.2% 0.0801
Last Price 0.0599
52-Week Low 0.0500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar